Certara, Inc. $CERT Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP lifted its stake in Certara, Inc. (NASDAQ:CERT) by 412.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 988,990 shares of the company’s stock after buying an additional 796,007 shares during the quarter. Quantinno Capital Management LP owned approximately 0.64% of Certara worth $5,637,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CERT. AQR Capital Management LLC acquired a new position in Certara in the first quarter valued at approximately $259,000. Goldman Sachs Group Inc. grew its stake in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after purchasing an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC increased its holdings in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Certara by 29.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock valued at $1,089,000 after purchasing an additional 21,099 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Up 1.5%

Shares of NASDAQ:CERT opened at $8.13 on Friday. The business’s 50 day moving average price is $6.52 and its 200-day moving average price is $6.54. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -18.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million during the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.Certara’s revenue was down 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.07 EPS. On average, equities research analysts forecast that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CERT. Stephens lowered their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings raised shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday. BMO Capital Markets decreased their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Craig Hallum lowered their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Finally, Morgan Stanley dropped their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.28.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.